^
BIOMARKER:

HR positive

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3




Show legend

Include preclinical:
HER2 Negative Breast Cancer
HER2 Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
Soft Tissue Sarcoma
Male Breast Cancer
Triple Negative Breast Cancer
Leiomyosarcoma
Breast Cancer
Ovarian Cancer
Aromatase inhibitor
CMF
EC-P
HER2 inhibitor
HER2 inhibitor + Aromatase inhibitor
EC
mTOR inhibitor + PI3K inhibitor + AKT inhibitor
CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor
Immunotherapy + PARP inhibitor
GnRH agonist
CDK4 inhibitor + CDK6 inhibitor
TCHP
PI3K inhibitor
ACT
tamoxifen
lapatinib
HDAC inhibitor + exemestane
trastuzumab + lapatinib
megestrol
vinorelbine
toremifene
exemestane
exemestane + mTOR inhibitor
denosumab
CT7001
fulvestrant
trastuzumab + neratinib
pembrolizumab
CDK4 inhibitor + CDK6 inhibitor + fulvestrant
capecitabine + DJ 927
PI3K inhibitor + fulvestrant
oral paclitaxel/encequidar
ABT-888
paclitaxel + cyclophosphamide + epirubicin
PF-05212384
palbociclib
ribociclib
abemaciclib
everolimus
olaparib
letrozole
trastuzumab
neratinib
capecitabine
alpelisib
Aromatase inhibitor + capecitabine
palbociclib + tucatinib
trastuzumab + abemaciclib
enzalutamide capsule
ST101
olaparib + durvalumab
rivoceranib
pyrotinib
entinostat
G1T38
U3-1402
PF-06873600
FCN-437
nivolumab + bevacizumab
palbociclib + abemaciclib
anlotinib
BPI-16350
PF-07220060
PF-07104091
SY-5609
trastuzumab + palbociclib + pertuzumab
LAE002
letrozole + dalpiciclib
RBN-2397
Zercepac (trastuzumab biosimilar)
sacituzumab govitecan-hziy
disitamab vedotin
ixazomib
DS-1062a
carboplatin + gemcitabine
docetaxel
dalpiciclib
eftilagimod alpha
chidamide
palbociclib + ribociclib
XZP 3287
fam-trastuzumab deruxtecan-nxki
albumin-bound paclitaxel
dalpiciclib + SHR 1020
everolimus + BI-836845
everolimus + letrozole + leuprolide acetate
trastuzumab + tucatinib
pazopanib
DJ 927
ribociclib + AN2025
cabozantinib capsule
trastuzumab duocarmazine
everolimus + abemaciclib
everolimus + ribociclib
epirubicin + vinorelbine tartrate
Z-endoxifen hydrochloride
AN2025
everolimus + tamoxifen
CB-228
abemaciclib + BI-836845
pyrotinib + dalpiciclib
pembrolizumab + SD-101
bevacizumab
eribulin mesylate
GDC-0032
pertuzumab + ado-trastuzumab emtansine
trastuzumab + pertuzumab
trastuzumab + pertuzumab + ado-trastuzumab emtansine
atezolizumab + RG7440
CX-2009
RP6530
palbociclib + RG7440
E7389-LF
nivolumab
capivasertib
pembrolizumab + abemaciclib
avelumab + talazoparib
pembrolizumab + palbociclib
palbociclib + ZW25
RG7440
atezolizumab + talimogene laherparepvec
pelareorep
nivolumab + talimogene laherparepvec
trastuzumab + palbociclib + pyrotinib
palbociclib + bosutinib
paclitaxel + pelareorep
TT-00420
gemcitabine
BLU-222
capecitabine + eribulin mesylate
talazoparib
ESG401
anastrozole
MK-2870
carboplatin + eribulin mesylate
gemcitabine + eribulin mesylate
atezolizumab + abemaciclib
ribociclib + BLU-222
SM08502
BTX-9341
ado-trastuzumab emtansine
palbociclib + BLU-222
sacituzumab govitecan-hziy + BAY 1895344
cisplatin
PMD-026
ACR-368
paclitaxel
camrelizumab + linperlisib
PCM-075
VIO-01